Covidien (NYSE:COV) said the lung biopsy device it acquired along with superDimension last year was included in new guidelines from the American College of Chest Physicians.
The superDimension electromagnetic navigation bronchoscopy system is designed to use the lungs own airways to obtain biopsies of suspect tissue earlier than other treatment options.
Mansfield, Mass.-based Covidien acquired superDimension in March 2012 for $300 million plus possible earnouts.
"Cancer patients, in general, benefit from diagnosis of their condition at the earliest possible stage, which may lead to earlier treatments and, potentially, more favorable outcomes,"Bryan Hanson, president of Covidien’s surgical solutions division, said in prepared remarks. "ENB is a minimally invasive approach to accessing difficult-to-reach lung lesions, which can lead to earlier diagnosis and treatment of cancer."
Covidien recently inked a deal with Vida Diagnostics to market Vida’s Apollo lung imaging system alongside its iLogic pulmonary navigation system.